Physician profile
Mark Anthony Williams
NPI 1972722288
$7,774.10
in general payments reported to CMS, 2019-2025
18 companies · $707 in 2025
The $707 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $178 · 2020: $159 · 2021: $2,523 · 2022: $1,184 · 2023: $583 · 2024: $2,441 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,723 · Travel and Lodging: $1,008.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,723.34 |
| Travel and Lodging | $1,007.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $3,149.30 | 2019-2025 | Xpress Ent Dilation System, Clarifix Cryotherapy Device, Scopis Ent |
| Aerin Medical INC. | $1,827.04 | 2019-2025 | |
| Genzyme Corporation | $673.14 | 2021-2025 | |
| Glaxosmithkline, LLC. | $345.53 | 2021-2025 | Nucala |
| Inspire Medical Systems, INC. | $341.91 | 2023-2024 | Inspire |
| Regeneron Healthcare Solutions, INC. | $338.13 | 2021-2025 | Dupixent |
| Intersect Ent, INC. | $237.00 | 2019-2021 | |
| Alk-Abello, INC | $217.14 | 2021-2022 | |
| Smith+Nephew, INC. | $179.25 | 2019-2024 | Tula, Coblation |
| Optinose US, INC. | $141.32 | 2021-2022 | |
| Genentech USA, INC. | $110.00 | 2019-2020 | |
| Integra Lifesciences Corporation | $83.95 | 2022 | |
| Phadia US INC. | $37.41 | 2024-2025 | Immunocap |
| Phathom Pharmaceuticals, INC. | $26.22 | 2024 | Voquezna |
| Acclarent, INC | $21.40 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $16.01 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $15.32 | 2023 | Seglentis |
| Astrazeneca Pharmaceuticals LP | $14.03 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.